Italian Biotech Giant Secures €83.5M for Revolutionary Heart Failure Therapy
Italian biotech company NanoPhoria Bioscience has secured €83.5 million in a Series A round, led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital. This significant investment will fuel the development of the company's lead therapy for heart failure with reduced ejection fraction (HFrEF), NP-MP1.
Investors, including Henrijette Richter of Sofinnova Partners, believe NanoPhoria's approach could revolutionize cardiovascular medicine. The company's CEO, Claudio De Luca, sees this financing as a transformational milestone, enabling clinical trials and pipeline expansion.
NP-MP1 targets L-type calcium channels to directly restore cardiac contractility and improve ejection fraction. In preclinical models, it has shown strong efficacy. The therapy is delivered via NanoPhoria's lung-to-heart nano-in-micro system, using inorganic calcium phosphate nanoparticles. This innovative approach could address the current gap in treatments that focus mainly on symptom reduction and disease progression.
With €83.5 million in funding, NanoPhoria Bioscience is poised to accelerate the development of NP-MP1. This therapy aims to directly restore heart contractility in patients with HFrEF, potentially offering a new hope for those affected by this condition.
Read also:
- Comprehensive Cancer Care Strategy Encompassed by Siemens Healthineers Entirely
- Fiercely battling for survival, a student hails from Ludwigsburg
- Mystery Disease Kills Thousands of Birds in Kazakhstan, Leaving Farmers in Limbo
- Recipients of 2024 ERC Starting Grants from the National Centre for Scientific Research (CNRS)
